Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials
Xiangying Yang,1 Xiaolu Chen,1 Yixiao Fu,2 Qinghua Luo,2 Lian Du,2 Haitang Qiu,2 Tian Qiu,2 Li Zhang,1 Huaqing Meng2 1The First Branch, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China; 2Department of Psychiatry, The First Affiliated Hos...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6aef1cf7e4794d7e8410b897e1943efc |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6aef1cf7e4794d7e8410b897e1943efc |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:6aef1cf7e4794d7e8410b897e1943efc2021-12-02T00:57:17ZComparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials1178-2021https://doaj.org/article/6aef1cf7e4794d7e8410b897e1943efc2018-05-01T00:00:00Zhttps://www.dovepress.com/comparative-efficacy-and-safety-of-crocus-sativus-l-for-treating-mild--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Xiangying Yang,1 Xiaolu Chen,1 Yixiao Fu,2 Qinghua Luo,2 Lian Du,2 Haitang Qiu,2 Tian Qiu,2 Li Zhang,1 Huaqing Meng2 1The First Branch, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China; 2Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China Purpose: To investigate the efficacy and safety of saffron in the treatment of major depressive disorder (MDD) in comparison to placebo and synthetic antidepressants. Patients and methods: We conducted a systematic search in several electronic databases as well as manual search in bibliographies of relevant studies. We included randomized controlled trials that investigated the efficacy and safety of saffron for treating MDD in adults in comparison to either placebo or synthetic antidepressants. Primary outcome was change in scores on depressive symptoms from baseline. Secondary outcomes included remission rate, response rate, and drop-out rate for all reasons. We chose a random-effects model in order to obtain more conservative results. Standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were estimated as the overall effect index by inverse variance models. Results: Seven studies were included in this meta-analysis. Overall quality of these included studies was moderate. As for the primary outcome, saffron showed more improvements in depression symptoms when compared with placebo, with an SMD of -1.22 (95% CI -1.94, -0.49, P=0.001). Meanwhile, saffron was as effective as synthetic antidepressants, with an SMD of 0.16 (95% CI -0.25, 0.57, P=0.44). Moderate heterogeneity existed in our analysis. Through subgroup analyses, we found that treatment dosage and duration, types of synthetic antidepressants administered in the comparison group, and outcome measures could explain most of the variance. No differences were found in remission rate, response rate, or drop-out rate. Conclusion: Saffron was effective in the treatment of MDD and had comparable efficacy to synthetic antidepressants. Saffron was also a safe drug without serious adverse events reported. Keywords: saffron, depression, efficacy, safety, meta-analysisYang XYChen XLFu YXLuo QHDu LQiu HTQiu TZhang LMeng HQDove Medical Pressarticlesaffrondepressionefficacysafetymeta-analysisNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 1297-1305 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
saffron depression efficacy safety meta-analysis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
saffron depression efficacy safety meta-analysis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Yang XY Chen XL Fu YX Luo QH Du L Qiu HT Qiu T Zhang L Meng HQ Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
| description |
Xiangying Yang,1 Xiaolu Chen,1 Yixiao Fu,2 Qinghua Luo,2 Lian Du,2 Haitang Qiu,2 Tian Qiu,2 Li Zhang,1 Huaqing Meng2 1The First Branch, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China; 2Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China Purpose: To investigate the efficacy and safety of saffron in the treatment of major depressive disorder (MDD) in comparison to placebo and synthetic antidepressants. Patients and methods: We conducted a systematic search in several electronic databases as well as manual search in bibliographies of relevant studies. We included randomized controlled trials that investigated the efficacy and safety of saffron for treating MDD in adults in comparison to either placebo or synthetic antidepressants. Primary outcome was change in scores on depressive symptoms from baseline. Secondary outcomes included remission rate, response rate, and drop-out rate for all reasons. We chose a random-effects model in order to obtain more conservative results. Standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were estimated as the overall effect index by inverse variance models. Results: Seven studies were included in this meta-analysis. Overall quality of these included studies was moderate. As for the primary outcome, saffron showed more improvements in depression symptoms when compared with placebo, with an SMD of -1.22 (95% CI -1.94, -0.49, P=0.001). Meanwhile, saffron was as effective as synthetic antidepressants, with an SMD of 0.16 (95% CI -0.25, 0.57, P=0.44). Moderate heterogeneity existed in our analysis. Through subgroup analyses, we found that treatment dosage and duration, types of synthetic antidepressants administered in the comparison group, and outcome measures could explain most of the variance. No differences were found in remission rate, response rate, or drop-out rate. Conclusion: Saffron was effective in the treatment of MDD and had comparable efficacy to synthetic antidepressants. Saffron was also a safe drug without serious adverse events reported. Keywords: saffron, depression, efficacy, safety, meta-analysis |
| format |
article |
| author |
Yang XY Chen XL Fu YX Luo QH Du L Qiu HT Qiu T Zhang L Meng HQ |
| author_facet |
Yang XY Chen XL Fu YX Luo QH Du L Qiu HT Qiu T Zhang L Meng HQ |
| author_sort |
Yang XY |
| title |
Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
| title_short |
Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
| title_full |
Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
| title_fullStr |
Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
| title_full_unstemmed |
Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
| title_sort |
comparative efficacy and safety of crocus sativus l. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials |
| publisher |
Dove Medical Press |
| publishDate |
2018 |
| url |
https://doaj.org/article/6aef1cf7e4794d7e8410b897e1943efc |
| work_keys_str_mv |
AT yangxy comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT chenxl comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT fuyx comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT luoqh comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT dul comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT qiuht comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT qiut comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT zhangl comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials AT menghq comparativeefficacyandsafetyofcrocussativuslfortreatingmildtomoderatemajordepressivedisorderinadultsametaanalysisofrandomizedcontrolledtrials |
| _version_ |
1718403389090430976 |